Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Eledon Pharmaceuticals Inc (NQ: ELDN ) 2.650 +0.170 (+6.85%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 20, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 152,373 Open 2.510 Bid (Size) 2.530 (4) Ask (Size) 2.880 (1) Prev. Close 2.480 Today's Range 2.480 - 2.670 52wk Range 1.070 - 3.349 Shares Outstanding 22,506,956 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference September 11, 2024 From Eledon Pharmaceuticals, Inc. Via GlobeNewswire Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients September 04, 2024 Enrollment Completed Four Months Ahead of Schedule From Eledon Pharmaceuticals, Inc. Via GlobeNewswire Performance YTD +40.96% +40.96% 1 Month -8.62% -8.62% 3 Month +1.53% +1.53% 6 Month +28.02% +28.02% 1 Year +119.01% +119.01% More News Read More ELDN Stock Earnings: Eledon Pharma Misses EPS for Q2 2024 August 19, 2024 Via InvestorPlace Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results August 14, 2024 From Eledon Pharmaceuticals, Inc. Via GlobeNewswire Eledon Pharmaceuticals Inc. (NASDAQ: ELDN) Leading the Way in Monday Trading Based on Percentage Gain April 22, 2024 Via Investor Brand Network Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection July 29, 2024 From Eledon Pharmaceuticals, Inc. Via GlobeNewswire Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism July 02, 2024 From Eledon Pharmaceuticals, Inc. Via GlobeNewswire Penny Stock Picks: 3 Companies Poised to Graduate to the Big Leagues June 17, 2024 Via InvestorPlace 3 High-Potential Penny Stocks to Turn $1000 into $1 Million: June 2024 June 11, 2024 Via InvestorPlace Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation June 03, 2024 From Eledon Pharmaceuticals, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Friday's After-Market Session May 17, 2024 Via Benzinga ELDN Stock Earnings: Eledon Pharma Beats EPS for Q1 2024 May 09, 2024 Via InvestorPlace Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results May 09, 2024 From Eledon Pharmaceuticals, Inc. Via GlobeNewswire Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress May 09, 2024 From Eledon Pharmaceuticals, Inc. Via GlobeNewswire Nano-Cap Eledon Pharmaceuticals' Investigational Drug Shows Safety In Early Organ Transplant Study, Analyst Boosts Forecast On Increased Confidence May 07, 2024 Via Benzinga 12 Health Care Stocks Moving In Tuesday's Pre-Market Session May 07, 2024 Via Benzinga Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection May 07, 2024 From Eledon Pharmaceuticals, Inc. Via GlobeNewswire Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement May 07, 2024 From Eledon Pharmaceuticals, Inc. Via GlobeNewswire ELDN Stock Earnings: Eledon Pharma Beats EPS for Q4 2023 March 28, 2024 Via InvestorPlace Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results March 28, 2024 From Eledon Pharmaceuticals, Inc. Via GlobeNewswire Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection March 25, 2024 From Eledon Pharmaceuticals, Inc. Via GlobeNewswire Kidney Transplant From Genetically Edited Pig: Boston Patient With End-Stage Renal Disease Becomes First To Receive March 21, 2024 Via Benzinga Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human March 21, 2024 From Eledon Pharmaceuticals, Inc. Via GlobeNewswire Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) February 13, 2024 From Eledon Pharmaceuticals, Inc. Via GlobeNewswire Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook January 04, 2024 From Eledon Pharmaceuticals, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.